Published in final edited form as:

Chem Rev. 2010 May 12; 110(5): 3043–3059. doi:10.1021/cr9004007.

Magnetic Resonance Spectroscopy in Metabolic and Molecular Imaging, and Diagnosis of Cancer

Kristine Glunde^{1,2,*}, Dmitri Artemov^{1,2}, Marie-France Penet, Michael A. Jacobs^{1,2}, and Zaver M. Bhujwala^{1,2,*}

¹JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD 21205

²Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21205

1. Introduction

Since its discovery in the 1940's, magnetic resonance (MR) spectroscopy (MRS) has developed into a major technique used by chemists to elucidate molecular structures. The underlying principle of MRS is the generation of radiofrequency (RF) signals by magnetic nuclear spins that are excited with a specific RF to precess in an external magnetic field B_0 . The magnetic resonance frequency ω_0 is linearly dependent on B_0 and the gyromagnetic ratio of the nucleus γ , as $\omega_0 = \gamma B_0$. The MR signal intensity depends on the concentration of nuclear spins, the magnetic field strength B_0 , and the gyromagnetic ratio γ of these spins. The magnetization signal in MRS is characterized by two rate constants, the spin-lattice (or longitudinal relaxation time) T_1 , and the spin-spin (or transverse relaxation time) T_2 . Since the resonance frequency of a particular nucleus is dependent upon its molecular structure, an important aspect of MRS is the ability to distinguish a nucleus with respect to its environment in the molecule. Because the molecular structure-based frequency shift and the resonance frequency are directly proportional to the strength of the magnetic field, the frequency shift is converted into a field-independent dimensionless value known as the chemical shift. Since the frequency shifts are extremely small in comparison to the resonance frequency, the chemical shift is expressed in parts per million (ppm). The chemical shift is typically reported relative to a reference resonance frequency. MRS therefore provides information about the chemical environment of the nuclear spin such as number of chemical bonds, neighboring nuclei, and overall chemical structure. As a result, each peak in an MR spectrum has a characteristic chemical shift that is dependent upon the chemical structure of the metabolite or compound, and a peak area that is proportional to the concentration of the compound. Scalar spin-spin interactions, or J-couplings, produce fine multiplet structures that can be used to further analyze the chemical structure of a given molecule.

Within the past two decades, the same principles of chemical shifts, magnetic moments, relaxation rates, and deriving concentrations from peak integrals have been applied in several preclinical and clinical studies to advance cancer discovery, diagnosis, and treatment. Incorporating imaging techniques with MRS has resulted in the development of MR spectroscopic imaging (MRSI) where the chemical information is spatially phase encoded,^{1–}

*Correspondence to: Kristine Glunde, Ph.D. Department of Radiology Johns Hopkins University School of Medicine 212 Traylor Bldg 720 Rutland Ave Baltimore, MD 21205 Tel: (410)-614-2705 Fax: (410)-614-1948 kglunde@mri.jhu.edu. Zaver M. Bhujwala, Ph.D. Department of Radiology Johns Hopkins University School of Medicine 208C Traylor Bldg 720 Rutland Ave Baltimore, MD 21205 Tel: (410)-955-9698 Fax: (410)-614-1948 zaver@mri.jhu.edu.

³ providing images of specific chemical compounds such as metabolites, reporter probes, labeled substrates, or drugs. The purpose of this article is to review recent developments and examples of the use of multi-nuclear MRS in cancer, and its integration with multi-modality imaging in cancer discovery and treatment.

The ability of cancer cells to adapt and survive treatments, and the collateral damage to normal cells as a result of several cancer treatments, continue to make the successful treatment of cancer a major challenge for the twenty first century. Tumor recurrence and metastasis are the leading causes of morbidity and mortality from cancer and, despite major advances in cancer research and treatment, cancer continues to evade cure. This is not surprising given the complexities of a tumor, and the genomic plasticity of cancer cells and stromal cells that are co-opted within the tumor. A schematic of the different components of a tumor is shown in Figure 1.

Physiological conditions such as hypoxia and acidic extracellular pH (pHe) that exist in the tumor microenvironment, the interactions between cancer cells and stromal cells such as endothelial cells, fibroblasts and macrophages, the extracellular matrix, and the numerous secreted factors and cytokines cumulatively influence progression, aggressiveness, and response of the disease to treatment. Hypoxia, in particular, is a major cause of radio- and chemo-resistance in cancer cells. Because of the remarkable ability of cancer cells to adapt and survive, finding effective treatments against cancer depends upon identifying and attacking targets and pathways critically important for the cancer cell. Multi-nuclear MRS provides unique opportunities for molecular and functional imaging of cancer in preclinical and clinical studies, and for imaging interactions between cancer cells and stromal cells. Some of these applications of MRS, the nuclei commonly studied, and the information that can be obtained are summarized in Table 1. From this table it is apparent that multi-nuclear noninvasive MRS methods have wide-ranging applications in cancer that can translate from bench to bedside. The chemical structures of various compounds referred to in this review article are summarized in Tables 2 and 3. Table 3 also provides details regarding administration and dose of the contrast agents described here.

The past decade has seen major advances in sequence design, development of novel reporter probes, and technological advances that have significantly increased the uses of MRS in molecular and functional imaging applications in oncology. Some of the recent applications of ¹H, ¹³C, ³¹P, and ¹⁹F MRS in preclinical models of cancer are reviewed, and examples of biomedical MRS applications for each nucleus are shown in Figure 2. New developments, such as hyperpolarization of spins to increase the sensitivity of detection of the MR signal of ¹³C-labeled substrates are discussed. Advantages and limitations of the spectroscopic techniques and challenges for the future are outlined.

The use of MR biomarkers such as the total choline (tCho) signal and perfusion are already being explored clinically for characterizing tumors and following treatment response.^{4–7} The elevation of choline compounds presents a unique target to exploit for molecular targeting; such targeting can be imaged noninvasively with MRS.^{8,9} Both pharmacological and molecular approaches are being developed to target choline metabolism, specifically choline kinase activity, which is the first step in choline phospholipid biosynthesis.

The interaction between cancer cells and the tumor microenvironment is providing new insights into the etiology and progression of cancer. For example, oxygen partial pressure (pO₂) in tumors can be imaged by both ¹H and ¹⁹F MRSI.^{10,11} Oxygen is sensed by administration of reporter molecules through changes in the spin-lattice relaxation rate. Integrating MRSI with MRI and other imaging modalities such as optical and nuclear imaging is providing useful insights into the dynamics between hypoxia and the tumor extracellular matrix (ECM),

vascularization, extracellular pH, interstitial fluid transport, and metabolism in preclinical models.^{12–14} These insights can be exploited to find effective treatment strategies.

2. Metabolic, Molecular, and Functional MRS of Cancer Cells and Their Microenvironment

2.1 Metabolic MRS

Along with, and frequently because of, aberrations in their genome and proteome, cancer cells exhibit a unique metabolic phenotype characterized by high glucose uptake, increased glycolytic activity and lactate production, decreased mitochondrial activity, low bioenergetic status, and aberrant phospholipid metabolism.^{15–18} In addition, tissue-specific metabolites such as N-acetyl aspartate in the brain, and citrate in the prostate, decrease as the cancer cell population in the tissue expands.^{18–22} The chemical structures of glucose, lactate, N-acetyl aspartate and citrate are shown in Table 2. MRS or MRSI detection of the ¹H or ³¹P MRS signals of these endogenous metabolites can assist in the diagnosis of cancer,^{23–46} and in monitoring anticancer therapy in cases where these metabolites have been established as surrogate markers for a specific therapy, as discussed in Section 3.2. Detection of aberrant metabolism with MRS can also lead to the identification of enzymes as novel anticancer targets.^{9,17,47–51}

Labeled Substrates—In addition to the detection of endogenous metabolites using ¹H or ³¹P MRS, ¹³C MRS detection of ¹³C-labeled metabolites can be performed following administration of suitable ¹³C-labeled substrates in cancer cells and solid tumors to study glycolysis (see Figure 2) or other metabolic pathways such as choline metabolism.⁸ The flux of substrates through metabolic pathways can be evaluated by detecting the incorporation of ¹³C label into downstream metabolites and products with ¹³C MRS, followed by metabolic modeling. The relatively low sensitivity of ¹³C MRS can be improved by a number of magnetization transfer techniques such as nuclear Overhauser effect (NOE), heteronuclear cross-polarization (HCP) experiments,⁵² and indirect inverse detection methods.⁵³ Such methods enable detecting ¹³C label with sensitivity close to that of ¹H MRS, which significantly increases the detection sensitivity of ¹³C-labeled metabolites *in vivo*. Weak ¹³C signals are enhanced by transferring strong magnetization from the neighboring protons *via* space using dipole-dipole spin coupling (in NOE methods) or through chemical bonds via J-coupling between ¹³C and ¹H spins. In direct detection methods such as NOE, distortionless enhancement by polarization transfer (DEPT), insensitive nuclei enhanced by polarization transfer (INEPT), and HCP the enhanced ¹³C signals are detected directly with broadband proton decoupling. In the indirect detection scheme, the magnetization is transferred from ¹H to ¹³C and then back to protons in heteronuclear multiple quantum coherence (HMQC) and heteronuclear single quantum coherence (HSQC) methods. The ¹³C signals are thus detected indirectly as ¹H frequencies with significantly enhanced sensitivity due to the higher gyromagnetic ratio γ of ¹H.⁵³

Glucose/Lactate—Cancer cells exhibit high glycolytic activity even in the presence of oxygen,^{54,55} an observation made by Otto Warburg in 1930 and subsequently called the 'Warburg Effect'. The molecular mechanisms underlying this aerobic glycolysis are mediated, in part, through the stabilization of the hypoxia inducible factor alpha (HIF-1 α).⁵⁵ HIF-1 α expression mediates the switch in glucose metabolism through the induction of lactate dehydrogenase, which converts pyruvate to lactate, and the inactivation of pyruvate dehydrogenase, the enzyme responsible for the conversion of pyruvate to acetyl-Coenzyme A.⁵⁶ The poor blood flow in tumors and the resulting hypoxia also contribute toward increasing anaerobic glycolysis.^{57,58} Glucose uptake within cells also increases through up-regulation of glucose transporter GLUT-1 and -3 expression, and possibly others GLUTs.^{59,60} As a result,

cancer cells rapidly metabolize glucose to form lactate. Intravenous infusion of [1-¹³C]-labeled glucose enables the investigation of glycolysis *in vivo*, and detection of the kinetics of [3-¹³C]-labeled lactate formation, as shown in the ¹³C MR spectra in Figure 2. Glucose uptake, delivery, and glycolytic breakdown, as well as lactate synthesis and clearance from the tumor can be derived by following the ¹³C-label of these substrates.⁶¹ Several factors, such as tumor hemodynamics, substrate supply, hypoxia, venous clearance, glucose supply, extent of necrosis, and degree of inflammatory cell infiltrate, contribute to lactate levels in tumors.⁶² Multiple signaling pathways and oncogenes can regulate glycolysis.⁵⁴ Decreasing tumor oxygenation correlated with increasing glycolytic rate in a murine mammary carcinoma model in a study using volume localized ¹³C MRS with ¹H-¹³C cross polarization to detect the conversion of [1-¹³C]-glucose to [3-¹³C]-lactate.⁶³ Several studies showed that [1-¹³C]-labeled glucose is metabolized to lactate in poorly differentiated tumors.^{64–67} High-resolution (HR) ¹³C MRS studies of tumor or organ extracts from animals infused with [1-¹³C]- or [U-¹³C]-labeled glucose reveal complex ¹³C-labeling patterns of various metabolites that can provide insight into metabolic compartmentalization, shuttling of metabolites between cell types or organs, and metabolic fluxes.⁶⁸ See Table 2 for the chemical structures of glucose, pyruvate, and lactate.

Hyperpolarization—The large increase of sensitivity introduced by the use of dynamic nuclear polarization (DNP) for solution-state magnetic resonance spectroscopy (DNP-MRS)⁶⁹ for *in vivo* MRS and MRSI detection of hyperpolarized ¹³C-labeled substrates has revitalized ¹³C MRS studies.^{70,71} Theoretically, DNP can increase the detection sensitivity of hyperpolarized ¹³C-labeled substrates and their metabolites by as much as 10,000-fold, without background signal from nonpolarized material.^{70,71} DNP is based on polarizing nuclear spins in the solid state.⁷² The mechanism requires the availability of unpaired electrons, which are added to the sample as homogeneously distributed organic free radicals before cooling the sample.⁶⁹ In the solid state, the high electron spin polarization is, in part, transferred to the nuclear spins by microwave irradiation, and subsequently brought into a liquid solution after rapid dissolution.⁶⁹ With this method, it is possible to bring the polarized, cold, solid sample into solution while preserving its nuclear polarization for a short time, sufficient for spectroscopic imaging.⁶⁹ However, complexities in terms of the chemistry of achieving hyperpolarization in the solid state, the appropriate free radicals, and the limited number of molecules amenable, reduce the achievable sensitivity. Commercial DNP-MR spectrometers and hyperpolarizers are currently becoming available. Elevated hyperpolarized lactate and possibly alanine produced from hyperpolarized [1-¹³C]-labeled pyruvate are being actively investigated as noninvasive biomarkers of cancer presence and histologic grade in preclinical models, which may be used in the future for the detection and management of cancer in humans.⁷¹ An alternative mechanism to hyperpolarize ¹³C nuclei includes the use of parahydrogen to hydrogenate multiple bonds in chemical structures containing enriched ¹³C isotopes (PASADENA).^{73,74} Parahydrogen based hyperpolarization requires ¹³C substrates with a specific chemical structure, which may limit its general applicability in comparison to DNP-based methods.

Choline phospholipid metabolism—Choline phospholipid metabolism is significantly altered in cancers, as validated by several preclinical and clinical studies.^{75–79} Almost all cancers display elevated phosphocholine (PC) and increased total choline-containing metabolites (total choline, tCho).^{75–79} A switch from high glycerophosphocholine (GPC)/low PC to low GPC/high PC can be detected following malignant transformation in breast⁸⁰ and ovarian⁸¹ cancer cells by HR ¹H or ³¹P MRS of cell extracts (see ¹H MRS of cell extract in Figure 2). These metabolic changes can be detected *in vivo*, and in biopsied tumor tissue *ex vivo* by ¹H or ³¹P MRS of the endogenous metabolites. The predominant ¹H MRS signals from water-soluble choline metabolism intermediates arise from the nine chemically equivalent

protons in the choline $-N(CH_3)_3$ groups between 3.2 – 3.3 ppm. Because nine protons contribute to the signal, it displays a relatively higher signal intensity than 1H signals detected in chemical groups with fewer equivalent protons. Free choline (Cho) is typically detected at 3.21 ppm, PC at 3.23 ppm, and GPC at 3.24 ppm, measured at pH 7.4 with 3-(trimethylsilyl) propionic-2,2,3,3- d_4 acid as a chemical shift reference, in HR MR spectra of cell or tissue extracts, or in HR magic angle spinning (MAS) MR spectra of biopsies. In the *in vivo* setting, the spectral resolution that can be achieved even at high magnetic fields is much lower, and unable to resolve Cho, PC, and GPC, as evident in the 1H MR spectra in Figure 2. Instead, an overlap of these three signals is detected as the tCho signal. The chemical structures of Cho, PC, and GPC are shown in Table 2.

Currently, clinical multi-center trials are underway to establish 1H MRS of a single voxel covering a region of interest, such as for example a lesion for breast cancer detection. Single-voxel 1H MRS detects a single localized MR spectrum. Alternatively *in vivo* 1H MRS imaging (MRSI) can be performed of one or multiple slice(s) through a region of interest. Multi-voxel techniques, in which multiple spectra are acquired over a slice or volume of tissue, enabling the detection of the spatial distribution of tCho (as well as other metabolites), are being developed. Such two-dimensional or three-dimensional MRSI have been used to detect elevated tCho *in vivo* in several types of cancer as discussed in Section 3. The phosphorus-containing choline metabolites can also be detected with ^{31}P MRS, as shown in Figure 2. HR ^{31}P MR spectra of extracts detect PC at 3.9 ppm and GPC at 0.5 ppm, upon chemical shift calibration to a reference compound, such as methylene diphosphonic acid at 18 ppm. Phosphorus MRS *in vivo* detects a mixed phosphomonoester (PME) signal comprising unresolved PC and phosphoethanolamine (PE) resonances, and a mixed phosphodiester (PDE) signal comprising unresolved GPC and glycerophosphoethanolamine (GPE) resonances. PC and PE, and/or GPE and GPC, can be partially resolved in clinical studies by using 1H -decoupled ^{31}P MRS techniques at 1.5 T,⁸² and at higher field strengths that are clinically available, such as 3T. However, *in vivo* clinical studies often favor 1H MRS because of its higher sensitivity and better availability on clinical scanners when compared to ^{31}P MRS. Neither 1H nor ^{31}P MRS in routine *in vivo* settings are able to spectrally resolve Cho, GPC, and PC as individual signals. As a consequence, non-invasively detected PME, PDE, and tCho changes in *in vivo* ^{31}P and 1H MR spectra, often arise from changes in the concentrations of several different metabolites. In some cases, this can be overcome by acquiring consecutive proton-decoupled ^{31}P and 1H MR spectra.⁸³ Recently, a novel 1H to ^{31}P polarization transfer method was developed on a clinical 3T MR scanner, which improved the signal-to-noise ratio by more than twofold compared to direct ^{31}P MRS methods.⁸⁴ This method achieved 1H to ^{31}P polarization transfer by applying chemical shift selective refocusing pulses at 3T, which cancelled the homonuclear J-coupling effects that attenuate ^{31}P signals in PE, PC, GPE, and GPC in previous refocused INEPT experiments.⁸⁴ The method allowed the identification of these four metabolites in human brains with a voxel size of $2 \times 2 \times 2 \text{ cm}^3$ in a three-dimensional MRSI data set.⁸⁴ The chemical structures of these metabolites are shown in Table 2.

The increased PC levels observed in cancer cells and tumors result from increased expression and activity of choline kinase,^{48–50} a higher rate of choline transport,^{85,86} and increased phospholipase C and D activity.^{81,87} These enzymes, amongst others, are involved in the biosynthetic and breakdown pathways of the major membrane phospholipid phosphatidylcholine (PtdCho), the precursors and breakdown products of which are GPC, PC, and Cho.⁸ Some of these enzymes, such as choline kinase^{9,17,47–51} and PtdCho-specific phospholipase D⁸⁸ and C,⁸¹ have recently been developed for MRS-monitored, targeted anticancer therapies, mediated by gene silencing or enzyme inhibition, as discussed in detail in Section 3.2. Enzymes in choline phospholipid metabolism are influenced by growth factor signaling, cytokine action, oncogene activation, and chemical carcinogenesis.^{17,75,76} The chemical structures of choline- and ethanolamine-related compounds are shown in Table 2.

Mobile lipids—*In vivo* single-voxel ^1H MRS and MRSI detect several signals that are related to choline and lipid metabolism, such as the total choline (tCho) signal at 3.2 ppm, the methylene signal at 1.3 ppm, and the methyl signal at 0.9 ppm (see representative ^1H MR spectra in Figure 2). These methylene and methyl signals arise from CH_2 and CH_3 groups in mobile lipids located in the cytoplasm of intact cancer cells, or in the intercellular space of solid tumors.^{89,90} The lipid signals at 1.3 and 0.9 ppm detected in intact cells and tumors *in vivo* have been assigned to the fatty acid acyl chains in triacylglycerides (see Table 2 for chemical structure) that form mobile lipid droplets.^{89,90} The low mobility of membrane lipids limits their detection by MRS *in vivo*, and therefore membrane lipids do not contribute to these lipid signals at 1.3 and 0.9 ppm.^{89,90} These lipid signals overlap with various other signals, such as lactate at 1.3 ppm, and spectral editing is required to separate these signals. Additional signals at 5.4 and 2.8 ppm can be assigned to mobile polyunsaturated fatty acyl chains to assess polyunsaturation of mobile lipids⁹⁰, although the signal at 5.4 ppm is difficult to detect due to its proximity to the large water signal at 4.7 ppm. High-grade human gliomas displayed significantly higher levels of lipid than low-grade gliomas, suggesting that the lipid signal at 1.3 ppm may prove useful in tumor grading.⁸⁹ Lipid droplets in tumors were also shown to correlate with drug resistance or response.⁸⁹ The cytoplasmic accumulation of triacylglycerides in cancer cells and tumors has been attributed to such diverse biological processes as hypoxia, degeneration of mitochondria, differentiation, growth arrest, and apoptotic cell death.^{89–91} Triacylglycerides are formed from increased diacylglycerol and triacylglycerol biosynthesis in lipid metabolism.^{90,91} Changes in the mobile lipid signal have also been observed following apoptosis, necrosis, or lipid droplets formation.^{92–94} MRS-visible lipids accumulate with apoptosis,⁹⁵ suggesting that this signal may serve as a surrogate marker for apoptosis, detected *in vivo* by ^1H MRS.

Energy Metabolism—While ^{31}P MRS is useful for detecting energy metabolism *in vivo*,^{96–99} it suffers from poor sensitivity, and therefore its use has declined in recent years, especially for clinical studies. Solid tumors contain nucleoside triphosphates (NTP), nucleoside diphosphates (NDP), phosphocreatine (PCr), and inorganic phosphate (Pi), all of which can be detected in ^{31}P MR spectra (see Figure 2). The chemical shift of the Pi resonance can be used to calculate the pH of the tumor as outlined in Section 2.3. Due to the Warburg effect, the bioenergetic state of cancer cells is relatively low.⁵⁴ Since the production of high energy phosphates such as NTP and PCr depend on glucose and oxygen, which are delivered to tumors through blood vessels, energy metabolism is tightly coupled to tumor blood flow,^{100,101} and decreases in hypoxic regions. Vaupel *et al.*^{57,58} observed a significant positive correlation between the ^{31}P MRS-detected ratios of PCr/Pi and NTP/Pi with tumor oxygenation. In preclinical studies, ^{31}P MRS may be useful in detecting blood flow mediated changes in tumor reoxygenation¹⁰² during radiation therapy.¹⁰³ The chemical structures of high-energy phosphates are shown in Table 2.

HR-MAS MRS—High-resolution magic angle spinning (HR MAS) ^1H MRS is a relatively new technology for examining intact biological tissue *ex vivo*, such as biopsy specimens, at high spectral resolution.^{22,104–109} One of the advantages of HR MAS ^1H MRS, in comparison to HR MRS of extracts, is that the tissue can be used subsequently for histologic, biochemical, and genetic analysis.^{22,104–109} HR MAS ^{31}P MRS is sensitive enough to be a potential future tool for assessing phospholipid metabolism in tumor samples prior to histopathologic examination.¹¹⁰

2.2 Molecular MRS

Magnetization transfer (MT) is a frequency selective MR technique that can be employed to evaluate ^1H and other nuclei chemical exchange to study chemical reactions.¹¹¹ Proton chemical-exchange-dependent saturation transfer (CEST) can provide, among other

applications, a strategy to measure pH *in vivo* as outlined in Section 2.3. Exogenous CEST-contrast agents have been tested, demonstrating the feasibility of detecting a CEST-based MRI contrast agent.¹¹² Detecting amide protons of endogenous mobile cellular proteins and peptides (see Table 3 for chemical structure, chemical shift of 8.3 ± 0.5 ppm) that undergo proton exchange with water has been demonstrated by ¹H MRS and MRI.¹¹³ Amide proton CEST contrast was achieved by selectively irradiating amide protons with a radiofrequency pulse at 8.3 ppm; water was imaged after several seconds of transfer, and the MT ratio asymmetry parameter calculated.¹¹³ Recently, a novel nonmetallic, biodegradable, lysine rich-protein (LRP) reporter was genetically engineered to provide a CEST reporter protein with frequency-selective contrast,¹¹⁴ as demonstrated in Figure 3. Similar to fluorescent proteins in optical imaging, such CEST reporter proteins can be used for molecular imaging studies in gene promoter or gene expression studies, in which ¹H MRI is used as the imaging modality. Figure 3A shows the principle of CEST. Frequency-selective radiofrequency pulses saturate the excitation of amide protons in LRP, which exchange with water protons and decrease the detected signal intensity (SI) of the water signal. Figure 3B and C show that *ex vivo* and *in vivo* LRP reporter imaging is feasible. To date, several different polypeptides have been tested for their feasibility as “multicolor” CEST reporters.¹¹⁵ These different CEST reporter proteins can be assigned artificial colors based on their particular amino acid units (lysine, arginine, threonine, or serine), which lead to different resonance frequencies of the exchangeable protons in different CEST reporters.¹¹⁵ These new CEST agents are potentially suitable for designing MR reporter genes for cell and tumor imaging, and for distinguishing multiple targets within the same MR image.¹¹⁵

2.3. The Tumor Microenvironment – Hypoxia and pH

The tumor microenvironment is usually characterized by areas of hypoxia, a neutral to alkaline intracellular pH (pHi), and an acidic extracellular pH (pHe).⁵⁷ Hypoxia arises in tumors from the chaotic and abnormal vasculature that results in areas with poor oxygenation and substrate supply.¹¹⁶ If the hypoxia is severe enough, these areas will ultimately progress to form necrosis. pHi depends upon the buffering capacity of the cell, the efficiency of proton pumps in the plasma membrane, and the rate of proton production.¹¹⁷ Extracellular pH also depends upon these factors, and additionally, on the ability of the vasculature to clear the protons.¹¹⁷ Both hypoxia and an acidic pHe result in a more aggressive phenotype,¹¹⁸ and hypoxia results in radiation- and chemo-resistance.¹¹⁹ MRS reporters that noninvasively measure pH and oxygen tension are therefore useful for selecting treatments and following changes in these parameters during treatment. Since these parameters are spatially heterogeneous, techniques that provide spatial information are the most useful. Global unlocalized information, however, is also valuable for understanding cancer pathophysiology and for developing effective therapeutic strategies that target hypoxia and pH.

Imaging Hypoxia by MRS/I—Perfluorocarbons (PFCs) have been used as probes to measure pO₂ using ¹⁹F MRS because their relaxivity is strongly dependent on the concentration of dissolved molecular oxygen.^{120–123} The advantages of ¹⁹F MRS-based oxygen probes are a relatively high sensitivity due to the large gyromagnetic ratio of the ¹⁹F nucleus, and the absence of endogenous ¹⁹F-containing molecules in the body. More recently, an analogous approach with ¹H MRS has been developed using hexamethyldisiloxane (HMDSO).¹¹ ¹H MRS has the highest sensitivity, but it is important that the reporter signal has a chemical shift that is well separated from metabolite signals and the water signal to avoid overlap. HMDSO has a single signal close to that of tetramethylsilane and is therefore well separated from metabolites and water. Ideally, these reporters should also have a single resonance, low temperature sensitivity, and display a linear response to pO₂. PFCs and HMDSO are poorly water-soluble, and therefore have to be administered as an emulsion. Intravenous administration of PFC emulsion results in uptake by the reticuloendothelial system, and the localization of the probe

in the tumor periphery, which may skew measurements towards well perfused regions.^{124–126} Alternatively, similar to the use of an Eppendorf electrode, the probes can be injected directly into the tissue to report on oxygen tensions in regions of interest, with the advantage of being able to follow oxygenation over a period of time.¹²⁷ Both ¹H MRS-detected HMDSO and the symmetric ¹⁹F MRS-detected PFC hexafluorobenzene (HFB) have a single resonance and a temperature-insensitive, oxygen-dependent relaxivity.¹²⁶ Both probes have previously been used to measure oxygen tensions in tumor models.¹²⁶ The high sensitivity of ¹⁹F and ¹H allow spatial localization for detection of these probes with an in-plane resolution of ~1 mm. The temporal resolution, which depends upon the ability to detect adequate signal at physiological non-toxic concentrations, is typically on the order of an hour or less. To date, these probes have not been used clinically.¹²⁶ The chemical structures of HMDSO and HFB are shown in Table 3.

Qualitative measurements of tumor hypoxia have also been performed using ¹⁹F MRS of reporter molecules such as nitroimidazoles, which accumulate in hypoxic cells.^{128,129} Nitroimidazoles are reduced by one-electron nitroreductase enzymes under hypoxic conditions to form reduction products that bind to endogenous cellular molecules. In the activation reaction, the addition of the first electron to form a nitroradical anion is reversible in the presence of oxygen. Therefore the process is dependent on oxygen concentration, and an accumulation of these reporters can be used to estimate hypoxia.¹³⁰ A potential problem is that two-electron reductases such as DT-diaphorase ([NAD(P)H:(quinone-acceptor) oxidoreductase, EC 1.6.99.2]) can reduce nitroimidazoles in two-electron steps, resulting in the reduction occurring independently of oxygen concentration.^{131,132} In addition, the adducts formed are short-lived.¹³²

Imaging Tumor pH by MRS/I—In 1973, Moon and Richards observed that the chemical shift of intracellular phosphates in whole blood was sensitive to pH.¹³³ This led to the development and use of the Pi peak to measure pH with MRS. Both intra- and extracellular Pi contribute to the Pi signal *in vivo* (see Table 3 for chemical structure). In tumors, the Pi signal is primarily of intracellular origin.¹³⁴ As a result, the chemical shift of Pi reports on intracellular pH (pHi). Since tumors are highly glycolytic, the concept of an acidic tumor pH had become commonly accepted until ³¹P MRS of tumors demonstrated that tumor intracellular pH was typically neutral or alkaline.¹³⁵ The subsequent development of an extracellular pH probe, 3-aminopropylphosphonate, 3-APP (for chemical structure see Table 3),^{136,137} allowed simultaneous detection of intra- and extracellular pH in tumors. These studies further confirmed that the extracellular pH (pHe) of tumors is acidic, while the intracellular pH (pHi) is neutral-to-alkaline. Acidic pHe has been observed to stimulate invasion in culture.¹³⁸ pH can be increased *in vivo* by chronic or acute treatment with bicarbonate.¹³⁹ Interestingly, a recent study has shown that mice treated with bicarbonate developed significantly fewer metastasis.¹⁴⁰ Phosphorus MRS has been used to measure pHi in human cancers,⁷⁵ but as yet probes to measure pHe in humans are not available. Other than acquiring spectra from 3–4 mm thick tumor slices or using large voxel sizes of ~6 × 6 × 6 mm³ localized on the tumor to avoid including signals from normal tissue, the low sensitivity of ³¹P MRS does not allow acquisition of spectra with high spatial resolution.

Several pH sensitive probes for ¹H and ¹⁹F MRS^{141–144} have been used to measure localized tumor pH using MRSI with spatial resolutions approaching 1 × 1 × 1 mm³.^{137,142,145,146} These pH probes are based on imidazole compounds.^{141,146,147} One imidazole-based compound, 2-imidazole-1-yl-ethoxy carbonyl propionic acid (IEPA, for chemical structure see Table 3), has been used to image tumor pHe in several tumor models. Consistent with earlier findings, the probe reported an acidic and heterogeneous pHe.^{137,142,148} IEPA has also been used in combination with vascular MRI to obtain co-localized multi-parametric data sets.¹⁴² By combining MRSI of pHe with vascular MRI measurements it is possible to exploit the multi-

parametric capability of MR to understand the dynamics between pHe and vascular parameters in tumors with different phenotypic characteristics.¹⁴²

Chemical exchange saturation transfer (CEST) has also been used to measure pH by determining the rate of acid-catalyzed exchange of exogenous or endogenous amide hydrogens with bulk water.^{112,113,149} CEST is relatively insensitive, requiring more than a 50 mM concentration of exchangeable amides (chemical structure shown in Table 3). Although the sensitivity of detection can be improved by using pH-sensitive paramagnetic lanthanide chelates (ParaCEST, see Table 3 for the chemical structure of a representative example),^{150–152} this approach still requires ~10 mM contrast agent and is also concentration dependent. Therefore, it is necessary to determine the concentration of the probe.¹⁵³ A recent approach of attaching a ¹⁹F-moiety on the same carrier as the pH-responsive paramagnetic complex provides a strategy to normalize the concentration of the probe.¹⁵⁴

One exciting development in the use of MRS to measure tumor pHe is the application of hyperpolarized ¹³C-labeled bicarbonate (see Table 3 for structure).¹⁵⁵ This nontoxic probe that can be infused in humans at relatively high concentrations, utilizes the cellular buffering systems to determine pHe. By DNP of ¹³C-bicarbonate, the sensitivity of ¹³C detection is increased by as much as 10,000-fold, which allows for ¹³C MRSI of tissues *in vivo*. The ratio of H¹³CO₃[–] to ¹³CO₂ is used to determine pH, assuming a pKa of 6.17. Initial preclinical studies demonstrated the feasibility of obtaining pHe maps with a spatial resolution of 2 × 2 × 6 mm³. The availability of such a nontoxic probe may be used, in the future, to image pH in humans not only in oncology but also in other disease processes with abnormal acid-base conditions.

3. MRS Applications in Diagnosis and Therapy Monitoring

3.1. Diagnosis

In vivo ¹H MRS provides clinically useful information and is routinely implemented in the majority of clinical MR scanners.^{23,37,42,156–159} In addition to standard dynamic contrast-enhanced (DCE) MR imaging (MRI), quantitative ¹H MRS and ¹H MRSI measurements of tCho, in addition to other tissue-specific metabolites, are increasingly being implemented to diagnose primary malignant tumors in brain,^{23–34} prostate,^{35–38} and breast.^{39–46,160} The addition of MRS to standard MRI techniques can lead to significant improvements in sensitivity of up to 88%, in specificity of greater than 90%, and diagnostic accuracy of up to 91%. Choline phospholipid metabolism intermediates, among other metabolites, can also serve as robust biomarkers *ex vivo*, when analyzed in human biopsy specimens using HR ¹H MRS or HR MAS ¹H MRS. High tCho and PC concentrations have been used to identify meningiomas and recurrent astrocytomas in human brain tissue specimens,¹⁶¹ breast cancer in fine-needle aspirates of breast tumors,¹⁶² prostatic carcinoma in postsurgical prostate tissue samples,²¹ and well-differentiated liposarcomas in surgically resected fat tissue specimens.²⁰

As discussed in detail in Section 2.1, significant spectral differences exist between normal tissue and tumors. One of the most reliable differences is observed in tCho, with low tCho concentration in normal tissue and high tCho levels in tumors.^{23,42,158,159} Proton MRS and MRSI can therefore be used clinically to help diagnose cancer, and to determine the margins of brain,^{23–25,163} prostate,^{158,159} and breast^{5,40–42,164,165} tumors, amongst others. Clinical ¹H MRS detection of tCho can also help differentiate tumor recurrence from necrosis following anti-tumor treatment in brain^{166–168} or prostate.¹⁶⁹ As single-voxel ¹H MRS or MRSI detects changes in tCho and other metabolites such as creatine, N-acetyl-aspartate (NAA), and lactate (see Table 2), obtaining metabolite ratios can improve the specificity of detection. Figure 4 shows an example of multiparametric MR of the prostate that includes an apparent diffusion coefficient (ADC) map from diffusion-weighted imaging (DWI), and three-

dimensional MRSI acquired at 1.5T. The three-dimensional MRSI spectral array in Figure 4B shows the presence of an aggressive tumor that contains elevated tCho and reduced citrate on the left side of the gland (right side of the image).¹⁷⁰

In current radiological practice, several MRI parameters, such as T₂-weighted contrast, T₁-weighted DCE-MRI, and DWI are combined to identify suspicious lesions in the prostate. Normal prostatic tissue has high T₂-weighted MRI signal, whereas low T₂-weighted MRI signal was found to correlate with pathological prostatic tissue.¹⁷¹ Studies at 3T have demonstrated an increase in sensitivity and specificity using T₂-weighted MRI, presumably due to increased signal-to-noise and contrast-to-noise ratios, as shown in Figure 5. Despite the improvement in visualization of prostate morphology using T₂-weighted MRI at 3T, there is a need for increased specificity, and for obtaining “functional” cellular and metabolic information from prostate tissue. This can be achieved by including MRSI.¹⁷² Adding MRSI can improve the reliable estimation of tumor margins and the extent of tumor infiltration into healthy tissue. However, a few benign and highly proliferative lesions can display relatively high tCho signals. In these cases, a differential diagnosis could be based on clinical information from other diagnostic scans.^{40–42,173} Another clinical application for single-voxel ¹H MRS, as well as ¹H MRSI, is in treatment planning for radiation¹⁷⁴ or brachytherapy.¹⁷⁵

3.2. Monitoring Therapy

Some of the most sought after goals in cancer management are the development of noninvasive biomarkers that predict risk, allow early identification, assist in the selection of treatment, and detect response.¹⁷⁶ Cancer cells have a remarkable ability to adapt and survive. Finding effective treatments against cancer depends upon identifying and attacking targets and pathways critically important for the cancer cell, with the additional caveat that each cancer represents an individual disease, and that no two cancers may be alike. As more critical targets in cancer cells are revealed, this decade is witnessing a transition in cancer treatment from the ‘sledgehammer’ approach of conventional chemo- and radiotherapy toward specific molecular targeting. The success of these molecular targeted treatments critically depends upon the availability of noninvasive imaging techniques to select targeted therapies that would be most effective against a particular cancer, and to detect response.¹⁷⁷ The identification of specific targets in cancer is also driving advances in novel image-guided platforms such as nanoparticles, liposomes, and microencapsulation devices to deliver small interfering RNA (siRNA)¹⁷⁸ or drugs to down regulate these targets and pathways.

Detection of early therapeutic response following treatment with traditional cytotoxic drugs is critically important to minimize damage to normal tissue in nonresponding tumors, and to alter the therapeutic strategy well before the full course of treatment. Single-voxel ¹H MRS and MRSI were found to be useful in assessing treatment response in brain,^{31,32,179} breast,^{5,164} and prostate¹⁵⁸ cancers. In breast cancer, several studies show that tCho has a high likelihood of detecting early response.¹⁸⁰ Response to primary systemic therapy (PST) of breast cancer was detected within 24 h of treatment by monitoring the change in tCho concentration,⁵ as evident in Figure 6. In this study MRI and MRS were performed on a 4T research MR scanner prior to treatment and within 24 h after treatment with combined doxorubicin and cyclophosphamide (see Figure 6). A lower tCho level compared to baseline was detected within 24 h with a further decrease after the fourth dose in patients who were objective responders (Figure 6). Total choline levels remained unchanged or increased in patients who were nonresponders (Figure 6).

Similar studies showed that the decrease in [tCho/citrate] ratios quantified from ¹H MR spectra could detect the response of prostate cancer to hormone-deprivation therapy^{158,159} and cryosurgery¹⁸¹ early on. Characteristic changes in choline phospholipid metabolites that were induced by anticancer treatments leading to apoptosis or necrosis were also reported.^{15,182,}

¹⁸³ Similarly, reduction of tCho has been associated with early response in lymphomas.¹⁸⁴ In some cancers, such as cervical cancer,¹⁸⁵ the tCho signal did not change following neoadjuvant treatment, but there was a reduction of tumor volume and the triglyceride signal.¹⁸⁵ The tumors were resected after treatment, but there were no differences in survival in patients with or without neoadjuvant therapy, and no survival advantage associated with reduction of tumor volume or decrease of triglycerides.¹⁸⁵

As molecular targeted preclinical studies are revealing, while a decrease of tCho and PC is observed following treatment with molecular targeting of several pathways, e.g. mitogen activated protein kinase (MAPK),¹⁸⁶ fatty acid synthase,¹⁸⁷ and Bcr-Abl tyrosine kinase,¹⁸⁸ the decrease of tCho or PC cannot always be associated with response, and depends upon the target selected. This was exemplified in a study showing that PC levels increased following histone deacetylase (HDAC) inhibition in cells.¹⁸⁹ However, PC levels did not change in tumors *in vivo* following HDAC inhibition.¹⁸⁹ This study also describes a novel fluorinated lysine derivative, which is a cleavable HDAC substrate that can be monitored by ¹⁹F MRS to detect HDAC activity.¹⁸⁹

Since one of the major causes of high PC in tumors is the increase in expression and activity of choline kinase (Chk), Chk presents an attractive target that can be exploited for cancer treatment.^{9,190–193} An additional advantage of targeting Chk is that the decrease of PC and tCho resulting from its downregulation can be detected noninvasively with ³¹P or ¹H MRS.^{190,191} Chk has been targeted with novel pharmacological inhibitors.^{192,193} Pharmacological inhibition of Chk was found to result in growth arrest and apoptosis.^{51,190} Chk has also been downregulated by RNA interference (RNAi).^{9,191} RNAi is a naturally occurring process that mediates sequence-specific inhibition of gene expression.^{194,195} Small interfering RNA (siRNA) is small double-stranded RNA of 19–23 nucleotides that can target virtually any gene and silence its expression.^{194,195} Downregulation of Chk- α with siRNA resulted in a significant reduction of cell proliferation and increased differentiation in highly invasive MDA-MB-231 human breast cancer cells, but not in non-malignant immortalized MCF-12A mammary epithelial cells.⁹ We subsequently used a lentiviral vector, injected intravenously, to deliver Chk-specific short-hairpin RNA (shRNA) in a breast cancer model.¹⁹¹ In this study, downregulation of Chk was monitored noninvasively by single-voxel ³¹P MRS as shown in Figure 7. We observed a reduction of PC and PME, which indicated that Chk was successfully downregulated in this lentiviral Chk-targeted gene therapy.¹⁹¹ Chk downregulation also resulted in a reduction of cell proliferation and tumor growth (see Figure 7). These studies demonstrate the feasibility of future gene therapy trials targeting Chk in tumors.

Recently, ¹³C MRSI of hyperpolarized ¹³C-labeled substrates, such as [1-¹³C]-pyruvate and [1,4-¹³C₂]-fumarate was used to detect treatment response in a murine lymphoma model.^{70,196} The chemical structures of these compounds are shown in Table 2. Tumor response was detected by a decrease in the flux of hyperpolarized ¹³C label between pyruvate and lactate in the case of [1-¹³C]-pyruvate, and an increase of [1,4-¹³C₂]-malate production in the case of [1,4-¹³C₂]-fumarate. The increase of [1,4-¹³C₂]-malate production was attributed to increased necrosis. These studies are important fore-runners of the use of hyperpolarized ¹³C-labeled substrates for detecting therapeutic response in tumors.

Poor drug delivery is another major problem in cancer chemotherapy, where MR methods can be used to directly determine the pharmacokinetics of a drug in the tumor, or to provide surrogate indices of drug uptake.^{197,198} Until recently, MR pharmacokinetic measurements of tumors *in vivo* were mainly restricted to fluorinated drugs such as [5-¹⁹F]-fluorouracil (5-FU, for chemical structure see Table 3) detected by ¹⁹F MRS,¹⁹⁹ because ¹⁹F MRS has the advantage of relatively high sensitivity and no background signal. Fluorine-19 MRS was used to detect the uptake and metabolism of the chemotherapeutic agent 5-FU in liver metastases

from colorectal cancer.²⁰⁰ In preclinical studies, we recently reported on image-guided delivery of a prodrug enzyme, bacterial cytosine deaminase (bCD), that converts nontoxic [5-¹⁹F]-fluorocytosine (5-FC, for chemical structure see Table 3) to 5-FU.²⁰¹ Visualization of the prodrug enzyme delivery was possible by conjugating it to poly-L-lysine functionalized with biotin, rhodamine, and Gd³⁺-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) for optical and MR imaging.²⁰¹ Image-guided timing of 5-FC prodrug administration to coincide with the maximum concentration of the enzyme in the tumor and the minimum concentration in normal tissue, minimized damage from the active drug 5-FU in normal tissue while maximizing damage to cancer cells.²⁰¹ The conversion of the prodrug 5-FC to the active drug 5-FU was detected by ¹⁹F MRS as shown in Figure 2.

For drugs lacking ¹⁹F atoms, chemical ¹⁹F-labeling may alter the physicochemical and pharmacological properties of the drug.^{202,203} The feasibility of ¹³C and ¹H MRS methods to detect drug uptake and distribution are therefore being explored.²⁰⁴ Such approaches depend upon the labeled drug having at least one well-resolved, isolated peak and being delivered at doses high enough to be within the detection sensitivity of MRS.²⁰⁵ Kato *et al.*²⁰⁴ were able to image the intratumoral distribution of the ¹³C-labeled anticancer agent temozolomide (see Table 3 for chemical structure) by ¹H/¹³C MRS. This ¹³C MRSI study demonstrated that temozolomide was heterogeneously delivered to the tumor.²⁰⁴ Temozolomide is used in the clinic for chemotherapy treatment of glioblastomas and anaplastic astrocytomas,²⁰⁶ and the preclinical studies with brain cancer models demonstrate the potential use of ¹³C MRS in detecting temozolomide delivery in human cancers.¹⁹⁸

4. Conclusions

Since the initial *in vivo* studies in the 1980's, multi-nuclear MRS has evolved into a highly versatile, noninvasive technique that is finding multiple applications in medical diagnosis, monitoring therapy, and research. Traditionally, MRS has provided biochemical characterization of pathological states. The increasing interface of chemistry with the fields of MRSI and molecular biology, and the resulting advances in theranostic contrast agent design, are providing new advances in the applications of MRS for molecular characterization and molecular-targeted medicine, especially in cancer. While sensitivity and spectral resolution continue to be limiting factors with this technique, the use of higher field strengths and the application of techniques such as hyperpolarization are providing advances that minimize these limitations.

The heterogeneity of tumors and the resulting heterogeneity of tumor response to treatment frequently result in cancer being an intractable disease, and make it imperative that each cancer is viewed individually in terms of the treatment selected and monitoring its response to treatment. The bench-to-bedside span of MRS, its ease of incorporation with MRI, and the multi-parametric information that can be obtained, make MRS a cornerstone technique for personalized medicine in cancer, in terms of predicting as well as detecting response to treatment.

Acknowledgments

Support from NIH P50 CA103175, P50 CA88843, P30 CA006973, U01 CA070095, U01 CA140204, R01 CA73850, R01 CA136576, R01 CA138515, R01 CA82337, R01 CA100184, R01 CA134695, R21 CA133288, and MD Stem Cells TEDCO 104026 is gratefully acknowledged.

Biographies

Dr. Kristine Glunde is Associate Professor of Radiology and Oncology at the Johns Hopkins University School of Medicine. She received her Ph.D. from the University of Bremen in Germany in 2000. She was a Postdoctoral Fellow in the Molecular Cancer Imaging Program in the Department of Radiology at the Johns Hopkins University (JHU) School of Medicine. Since 2003, she has been a faculty member in the JHU *In Vivo* Cellular and Molecular Imaging Center (JHU ICMIC Program). Dr. Glunde's research focusses on developing novel optical imaging agents and techniques to study the role of lysosomal trafficking in breast and prostate cancer invasion and metastasis. She also studies mechanisms underlying the aberrant choline phospholipid metabolism in breast and prostate cancer using magnetic resonance spectroscopy and imaging mass spectrometry.

Dr. Dmitri Artemov is Associate Professor of Radiology and Oncology at the Johns Hopkins University (JHU) School of Medicine. He received his Ph.D. from the Russian Academy of Sciences, Moscow. Before joining the JHU faculty, Dr. Artemov completed his postdoctoral training at the University of Wuerzburg and the Department of Radiology at the JHU School of Medicine. Dr. Artemov's research interests focus on developing novel molecular MR imaging methods to study tumors, and on the role of stem cells in tumor progression and therapy.

Dr. Marie-France Penet is an Instructor in the Molecular Cancer Imaging Program in the Department of Radiology at the Johns Hopkins University (JHU) School of Medicine. She received her Ph.D. degree from the University of Aix-Marseille in France in 2005. Dr. Penet's research focuses on using magnetic resonance imaging and spectroscopy together with histological and molecular analyses to understand the role of hypoxia and tumor vascularization and metabolism in prostate cancer invasion and metastasis.

Dr. Michael A. Jacobs is Associate Professor of Radiology and Oncology at the Johns Hopkins University (JHU) School of Medicine. His current research interests include developing radiological methods for detection, monitoring, and treatment of different pathologies. For example, using advanced MR methods for identification and classification of breast, prostate, and metastatic cancer, stroke, and uterine fibroids. He has pioneered the development of multi-parametric analysis of different pathologies that can combine different modalities to derive diagnostic biomarkers, as well as investigating the use of thermotherapy for treatment of tumors. Dr. Jacobs is on the National Board of the American College of Radiology Imaging Network (ACRIN) Breast Imaging committee and is the member of the subcommittee of

molecular and functional imaging of the ACRIN. In addition, he is the Co-director of the Imaging Radiological Assessment Team (IRAT) at Johns Hopkins.

Dr. Zaver M. Bhujwalla is Professor in the Departments of Radiology and Oncology at the Johns Hopkins University (JHU) School of Medicine. She is the Director of the JHU *In Vivo* Cellular and Molecular Imaging Center. Dr. Bhujwalla joined the Department of Radiology at the Johns Hopkins University School of Medicine in 1989, just after completing her Ph.D. from the University of London. Dr. Bhujwalla's work has focused on the applications of MR imaging and spectroscopy and more recently multi-modality imaging to understand and treat cancer. Dr. Bhujwalla is an elected Fellow of the International Society of Magnetic Resonance

in Medicine, and the American Institute of Biomedical Engineers. Dr. Bhujwalla is associated with the editorial boards of Molecular Imaging, NMR in Biomedicine, Cancer Biology and Therapy, and Contrast Media and Molecular Imaging.

5. References

- (1). Brown TR, Kincaid BM, Ugurbil K. Proc Natl Acad Sci U S A 1982;79:3523–6. [PubMed: 6954498]
- (2). Haselgrove JC, Subramanian VH, Leigh JS Jr. Gyulai L, Chance B. Science 1983;220:1170–3. [PubMed: 6857240]
- (3). Maudsley AA, Hilal SK, Perman WH, Simon HE. Journal of Magnetic Resonance 1983;51:147–152.
- (4). Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. Radiol Clin North Am 2000;38:115–38. viii–ix. [PubMed: 10664669]
- (5). Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Radiology 2004;233:424–31. [PubMed: 15516615]
- (6). Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioğlu O, Su MY. Radiology 2009;251:653–62. [PubMed: 19276320]
- (7). Kumar V, Jagannathan NR, Kumar R, Das SC, Jindal L, Thulkar S, Gupta SD, Dwivedi SN, Roell S, Hemal AK, Gupta NP. Magn Reson Imaging 2006;24:541–548. [PubMed: 16735174]
- (8). Glunde K, Jie C, Bhujwalla ZM. Cancer Res 2004;64:4270–6. [PubMed: 15205341]
- (9). Glunde K, Raman V, Mori N, Bhujwalla ZM. Cancer Res 2005;65:11034–43. [PubMed: 16322253]
- (10). Zhao D, Ran S, Constantinescu A, Hahn EW, Mason RP. Neoplasia 2003;5:308–18. [PubMed: 14511402]
- (11). Kodibagkar VD, Cui W, Merritt ME, Mason RP. Magn Reson Med 2006;55:743–8. [PubMed: 16506157]
- (12). Raman V, Artemov D, Pathak AP, Winnard PT Jr. McNutt S, Yudina A, Bogdanov A Jr. Bhujwalla ZM. Cancer Res 2006;66:9929–36. [PubMed: 17047055]
- (13). Glunde K, Shah T, Winnard PTJ, Raman V, Takagi T, Vesuna F, Artemov D, Bhujwalla ZM. Cancer Res 2008;68:172–80. [PubMed: 18172309]
- (14). Penet MF, Pathak AP, Raman V, Ballesteros P, Artemov D, Bhujwalla ZM. Cancer Res 2009;69:8822–9. [PubMed: 19861534]
- (15). Griffin JL, Shockcor JP. Nat Rev Cancer 2004;4:551–61. [PubMed: 15229480]
- (16). Griffin JL, Kauppinen RA. J Proteome Res 2007;6:498–505. [PubMed: 17269706]
- (17). Glunde K, Serkova NJ. Pharmacogenomics 2006;7:1109–23. [PubMed: 17054420]
- (18). Costello LC, Franklin RB. Mol Cell Biochem 2005;280:1–8. [PubMed: 16511951]
- (19). Griffin JL, Kauppinen RA. Febs J 2007;274:1132–9. [PubMed: 17298437]
- (20). Millis K, Weybright P, Campbell N, Fletcher JA, Fletcher CD, Cory DG, Singer S. Magn Reson Med 1999;41:257–67. [PubMed: 10080272]
- (21). Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J. Magn Reson Med 2003;50:944–54. [PubMed: 14587005]
- (22). Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K, Vigneron DB, Kurhanewicz J. Magn Reson Med 2006;55:1257–64. [PubMed: 16685733]
- (23). Barker PB, Glickson JD, Bryan RN. Top Magn Reson Imaging 1993;5:32–45. [PubMed: 8416687]
- (24). Pouwels PJ, Frahm J. Magn Reson Med 1998;39:53–60. [PubMed: 9438437]
- (25). Ross B, Michaelis T. Magn Reson Q 1994;10:191–247. [PubMed: 7873353]
- (26). Chang L, McBride D, Miller BL, Cornford M, Booth RA, Buchthal SD, Ernst TM, Jenden D. J Neuroimaging 1995;5:157–63. [PubMed: 7626823]
- (27). Tzika AA, Cheng LL, Goumnerova L, Madsen JR, Zurakowski D, Astrakas LG, Zarifi MK, Scott RM, Anthony DC, Gonzalez RG, Black PM. J Neurosurg 2002;96:1023–31. [PubMed: 12066902]
- (28). Nelson SJ. Magn Reson Med 2001;46:228–39. [PubMed: 11477625]
- (29). Howe FA, Barton SJ, Cudlip SA, Stubbs M, Saunders DE, Murphy M, Wilkins P, Opstad KS, Doyle VL, McLean MA, Bell BA, Griffiths JR. Magn Reson Med 2003;49:223–32. [PubMed: 12541241]

- (30). Murphy M, Loosemore A, Clifton AG, Howe FA, Tate AR, Cudlip SA, Wilkins PR, Griffiths JR, Bell BA. *Br J Neurosurg* 2002;16:329–34. [PubMed: 12389884]
- (31). Lindskog M, Spenger C, Klason T, Jarvet J, Graslund A, Johnsen JI, Ponthan F, Douglas L, Nordell B, Kogner P. *Cancer Lett* 2005;228:247–55. [PubMed: 15946794]
- (32). Jenkinson MD, Smith TS, Joyce K, Fildes D, du Plessis DG, Warnke PC, Walker C. *Neurology* 2005;64:2085–9. [PubMed: 15985578]
- (33). Jeun SS, Kim MC, Kim BS, Lee JM, Chung ST, Oh CH, Lee SY, Choe BY. *Clin Imaging* 2005;29:10–5. [PubMed: 15859012]
- (34). McKnight TR. *Semin Oncol* 2004;31:605–17. [PubMed: 15497114]
- (35). Narayan P, Kurhanewicz J. *Prostate Suppl* 1992;4:43–50. [PubMed: 1374177]
- (36). Schick F, Bongers H, Kurz S, Jung WI, Pfeffer M, Lutz O. *Magn Reson Med* 1993;29:38–43. [PubMed: 8110206]
- (37). Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. *Radiology* 1996;198:795–805. [PubMed: 8628874]
- (38). Menard C, Smith IC, Somorjai RL, Leboldus L, Patel R, Littman C, Robertson SJ, Bezabeh T. *Int J Radiat Oncol Biol Phys* 2001;50:317–23. [PubMed: 11380217]
- (39). Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Coshic O, Julka PK, Rath GK. *NMR Biomed* 1998;11:414–22. [PubMed: 10221584]
- (40). Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. *Radiology* 1998;209:269–275. [PubMed: 9769842]
- (41). Yeung DK, Cheung HS, Tse GM. *Radiology* 2001;220:40–6. [PubMed: 11425970]
- (42). Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. *J Magn Reson Imaging* 2004;19:68–75. [PubMed: 14696222]
- (43). Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M. *Magn Reson Med* 2003;50:1134–43. [PubMed: 14648561]
- (44). Meisamy S, Bolan PJ, Baker EH, Pollema MG, Le CT, Kelcz F, Lechner MC, Luikens BA, Carlson RA, Brandt KR, Amrami KK, Nelson MT, Everson LI, Emory TH, Tuttle TM, Yee D, Garwood M. *Radiology* 2005;236:465–75. [PubMed: 16040903]
- (45). Stanwell P, Gluch L, Clark D, Tomanek B, Baker L, Giuffre B, Lean C, Malycha P, Mountford C. *Eur Radiol* 2005;15:1037–43. [PubMed: 15351906]
- (46). Baik HM, Su MY, Yu H, Nalcioğlu O, Mehta R. *Magma* 2006;19:96–104. [PubMed: 16779565]
- (47). Ramirez de Molina A, Gallego-Ortega D, Sarmentero J, Banez-Coronel M, Martin-Cantalejo Y, Lacal JC. *Cancer Res* 2005;65:5647–53. [PubMed: 15994937]
- (48). Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. *Oncogene* 2002;21:4317–22. [PubMed: 12082619]
- (49). Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. *Oncogene* 2002;21:937–46. [PubMed: 11840339]
- (50). Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J. *Biochem Biophys Res Commun* 2002;296:580–3. [PubMed: 12176020]
- (51). Rodriguez-Gonzalez A, Ramirez de Molina A, Fernandez F, Lacal JC. *Oncogene* 2004;23:8247–59. [PubMed: 15378008]
- (52). Artemov D, Bhujwalla ZM, Glickson JD. *Magn Reson Med* 1995;33:151–5. [PubMed: 7707903]
- (53). van Zijl PC, Chesnick AS, DesPres D, Moonen CT, Ruiz-Cabello J, van Gelderen P. *Magn Reson Med* 1993;30:544–51. [PubMed: 8259054]
- (54). Vander Heiden MG, Cantley LC, Thompson CB. *Science* 2009;324:1029–33. [PubMed: 19460998]
- (55). Kim JW, Dang CV. *Cancer Res* 2006;66:8927–30. [PubMed: 16982728]
- (56). Semenza GL. *Biochem J* 2007;405:1–9. [PubMed: 17555402]
- (57). Vaupel P, Kallinowski F, Okunieff P. *Cancer Res* 1989;49:6449–65. [PubMed: 2684393]
- (58). Vaupel P, Okunieff P, Kallinowski F, Neuringer LJ. *Radiat Res* 1989;120:477–93. [PubMed: 2594969]
- (59). Medina RA, Owen GI. *Biol Res* 2002;35:9–26. [PubMed: 12125211]
- (60). Macheda ML, Rogers S, Best JD. *J Cell Physiol* 2005;202:654–62. [PubMed: 15389572]

- (61). Rivenzon-Segal D, Margalit R, Degani H. *Am J Physiol Endocrinol Metab* 2002;283:E623–30. [PubMed: 12217878]
- (62). Terpstra M, High WB, Luo Y, de Graaf RA, Merkle H, Garwood M. *NMR Biomed* 1996;9:185–94. [PubMed: 9067999]
- (63). Nielsen FU, Daugaard P, Bentzen L, Stodkilde-Jorgensen H, Overgaard J, Horsman MR, Maxwell RJ. *Cancer Res* 2001;61:5318–25. [PubMed: 11431377]
- (64). Constantinidis I, Chatham JC, Wehrle JP, Glickson JD. *Magn Reson Med* 1991;20:17–26. [PubMed: 1943658]
- (65). Bhujwala ZM, Constantinidis I, Chatham JC, Wehrle JP, Glickson JD. *Int J Radiat Oncol Biol Phys* 1992;22:95–101. [PubMed: 1727132]
- (66). Schupp DG, Merkle H, Ellermann JM, Ke Y, Garwood M. *Magn Reson Med* 1993;30:18–27. [PubMed: 8371670]
- (67). Artemov D, Bhujwala ZM, Pilatus U, Glickson JD. *NMR Biomed* 1998;11:395–404. [PubMed: 10221582]
- (68). Bouzier AK, Quesson B, Valeins H, Canioni P, Merle M. *J Neurochem* 1999;72:2445–55. [PubMed: 10349854]
- (69). Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. *Proc Natl Acad Sci U S A* 2003;100:10158–63. [PubMed: 12930897]
- (70). Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KM. *Nat Med* 2007;13:1382–7. [PubMed: 17965722]
- (71). Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J. *Cancer Res* 2008;68:8607–15. [PubMed: 18922937]
- (72). Abragam AA, Proctor WG. *Phys Rev* 1958;109
- (73). Goldman M, Johannesson H, Axelsson O, Karlsson M. *Magn Reson Imaging* 2005;23:153–7. [PubMed: 15833606]
- (74). Johansson E, Olsson LE, Mansson S, Petersson JS, Golman K, Stahlberg F, Wirestam R. *Magn Reson Med* 2004;52:1043–51. [PubMed: 15508152]
- (75). Negendank W. *NMR Biomed* 1992;5:303–24. [PubMed: 1333263]
- (76). Podo F. *NMR Biomed* 1999;12:413–39. [PubMed: 10654290]
- (77). Ronen SM, Leach MO. *Breast Cancer Res* 2001;3:36–40. [PubMed: 11250743]
- (78). Ackerstaff E, Glunde K, Bhujwala ZM. *J Cell Biochem* 2003;90:525–33. [PubMed: 14523987]
- (79). Franks SE, Smith MR, Arias-Mendoza F, Shaller C, Padavic-Shaller K, Kappler F, Zhang Y, Negendank WG, Brown TR. *Leuk Res* 2002;26:919–26. [PubMed: 12163053]
- (80). Aboagye EO, Bhujwala ZM. *Cancer Res* 1999;59:80–4. [PubMed: 9892190]
- (81). Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F. *Cancer Res* 2005;65:9369–76. [PubMed: 16230400]
- (82). Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, Ballon D, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR. *NMR Biomed* 2006;19:504–12. [PubMed: 16763965]
- (83). Albers MJ, Krieger MD, Gonzalez-Gomez I, Gilles FH, McComb JG, Nelson MD Jr, Bluml S. *Magn Reson Med* 2005;53:22–9. [PubMed: 15690498]
- (84). Klomp DW, Wijnen JP, Scheenen TW, Heerschap A. *Magn Reson Med* 2008;60:1298–305. [PubMed: 19030163]
- (85). Katz-Brull R, Degani H. *Anticancer Res* 1996;16:1375–80. [PubMed: 8694504]
- (86). Eliyahu G, Kreizman T, Degani H. *Int J Cancer* 2007;120:1721–30. [PubMed: 17236204]
- (87). Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS. *Cancer Lett* 2000;161:207–14. [PubMed: 11090971]
- (88). Foster DA, Xu L. *Mol Cancer Res* 2003;1:789–800. [PubMed: 14517341]
- (89). Gillies RJ, Morse DL. *Annu Rev Biomed Eng* 2005;7:287–326. [PubMed: 16004573]
- (90). Hakumaki JM, Poptani H, Sandmair AM, Yla-Herttuala S, Kauppinen RA. *Nat Med* 1999;5:1323–7. [PubMed: 10546002]

- (91). Engelmann J, Henke J, Willker W, Kutscher B, Nossner G, Engel J, Leibfritz D. *Anticancer Res* 1996;16:1429–39. [PubMed: 8694511]
- (92). Al-Saffar NM, Titley JC, Robertson D, Clarke PA, Jackson LE, Leach MO, Ronen SM. *Br J Cancer* 2002;86:963–70. [PubMed: 11953830]
- (93). Barba I, Cabanas ME, Arus C. *Cancer Res* 1999;59:1861–8. [PubMed: 10213493]
- (94). Callies R, Sri-Pathmanathan RM, Ferguson DY, Brindle KM. *Magn Reson Med* 1993;29:546–50. [PubMed: 8464371]
- (95). Schmitz JE, Kettunen MI, Hu DE, Brindle KM. *Magn Reson Med* 2005;54:43–50. [PubMed: 15968678]
- (96). Ackerman JJ, Grove TH, Wong GG, Gadian DG, Radda GK. *Nature* 1980;283:167–70. [PubMed: 7350541]
- (97). Griffiths JR, Cady E, Edwards RH, McCready VR, Wilkie DR, Wiltshaw E. *Lancet* 1983;1:1435–6. [PubMed: 6134191]
- (98). Bottomley PA, Charles HC, Roemer PB, Flamig D, Engeseth H, Edelstein WA, Mueller OM. *Magn Reson Med* 1988;7:319–36. [PubMed: 3205148]
- (99). Hardy CJ, Bottomley PA, Roemer PB, Redington RW. *Magn Reson Med* 1988;8:104–9. [PubMed: 3173064]
- (100). Okunieff PG, Koutcher JA, Gerweck L, McFarland E, Hitzig B, Urano M, Brady T, Neuringer L, Suit HD. *Int J Radiat Oncol Biol Phys* 1986;12:793–9. [PubMed: 3710861]
- (101). Li SJ, Wehrle JP, Rajan SS, Steen RG, Glickson JD, Hilton J. *Cancer Res* 1988;48:4736–42. [PubMed: 3409214]
- (102). Kallman RF. *Radiology* 1972;105:135–42. [PubMed: 4506641]
- (103). Tozer GM, Griffiths JR. *NMR Biomed* 1992;5:279–89. [PubMed: 1449969]
- (104). Cheng LL, Chang IW, Louis DN, Gonzalez RG. *Cancer Res* 1998;58:1825–32. [PubMed: 9581820]
- (105). Cheng LL, Chang IW, Smith BL, Gonzalez RG. *J Magn Reson* 1998;135:194–202. [PubMed: 9799694]
- (106). Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, Wu CL. *Cancer Res* 2005;65:3030–4. [PubMed: 15833828]
- (107). Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. *NMR Biomed* 2006;19:30–40. [PubMed: 16229059]
- (108). Sitter B, Sonnewald U, Spraul M, Fjosne HE, Gribbestad IS. *NMR Biomed* 2002;15:327–37. [PubMed: 12203224]
- (109). Martinez-Bisbal MC, Marti-Bonmati L, Piquer J, Revert A, Ferrer P, Llacer JL, Piotto M, Assemat O, Celda B. *NMR Biomed* 2004;17:191–205. [PubMed: 15229932]
- (110). Payne GS, Troy H, Vaidya SJ, Griffiths JR, Leach MO, Chung YL. *NMR Biomed*. 2006
- (111). Alger JR, Shulman RG. *Q Rev Biophys* 1984;17:83–124. [PubMed: 6091170]
- (112). Ward KM, Aletras AH, Balaban RS. *J Magn Reson* 2000;143:79–87. [PubMed: 10698648]
- (113). Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. *Nat Med* 2003;9:1085–90. [PubMed: 12872167]
- (114). Gilad AA, McMahon MT, Walczak P, Winnard PT Jr. Raman V, van Laarhoven HW, Skoglund CM, Bulte JW, van Zijl PC. *Nat Biotechnol* 2007;25:217–9. [PubMed: 17259977]
- (115). McMahon MT, Gilad AA, DeLiso MA, Berman SM, Bulte JW, van Zijl PC. *Magn Reson Med* 2008;60:803–12. [PubMed: 18816830]
- (116). Jain RK. *Cancer Res* 1988;48:2641–58. [PubMed: 3282647]
- (117). Gatenby RA, Gillies RJ. *Nat Rev Cancer* 2004;4:891–9. [PubMed: 15516961]
- (118). Lunt SJ, Chaudary N, Hill RP. *Clin Exp Metastasis* 2009;26:19–34. [PubMed: 18543068]
- (119). Rockwell S, Dobrucki IT, Kim EY, Marrison ST, Vu VT. *Curr Mol Med* 2009;9:442–58. [PubMed: 19519402]
- (120). Parhami P, Fung BM. *Journal of Physical Chemistry* 1983;87:1928–1931.
- (121). Zhao D, Jiang L, Mason RP. *Methods Enzymol* 2004;386:378–418. [PubMed: 15120262]
- (122). Dardzinski BJ, Sotak CH. *Magn Reson Med* 1994;32:88–97. [PubMed: 8084241]

- (123). Jordan BF, Cron GO, Gallez B. *Magn Reson Med* 2009;61:634–8. [PubMed: 19097235]
- (124). Baldwin NJ, Ng TC. *Magn Reson Imaging* 1996;14:541–51. [PubMed: 8843366]
- (125). Mason RP, Antich PP, Babcock EE, Constantinescu A, Peschke P, Hahn EW. *Int J Radiat Oncol Biol Phys* 1994;29:95–103. [PubMed: 8175452]
- (126). Kodibagkar VD, Wang X, Mason RP. *Front Biosci* 2008;13:1371–84. [PubMed: 17981636]
- (127). Kodibagkar VD, Wang X, Pacheco-Torres J, Gulaka P, Mason RP. *NMR Biomed* 2008;21:899–907. [PubMed: 18574806]
- (128). Aboagye EO, Kelson AB, Tracy M, Workman P. *Anticancer Drug Des* 1998;13:703–30. [PubMed: 9755726]
- (129). Prociassi D, Claus F, Burgman P, Kozirowski J, Chapman JD, Thakur SB, Matei C, Ling CC, Koutcher JA. *Clin Cancer Res* 2007;13:3738–47. [PubMed: 17575240]
- (130). Varghese AJ, Gulyas S, Mohindra JK. *Cancer Res* 1976;36:3761–5. [PubMed: 986241]
- (131). Kizaka-Kondoh S, Konse-Nagasawa H. *Cancer Sci* 2009;100:1366–73. [PubMed: 19459851]
- (132). Laughlin KM, Evans SM, Jenkins WT, Tracy M, Chan CY, Lord EM, Koch CJ. *J Pharmacol Exp Ther* 1996;277:1049–57. [PubMed: 8627516]
- (133). Moon RB, Richards JH. *J Biol Chem* 1973;248:7276–8. [PubMed: 4743524]
- (134). Stubbs M, Bhujwalla ZM, Tozer GM, Rodrigues LM, Maxwell RJ, Morgan R, Howe FA, Griffiths JR. *NMR Biomed* 1992;5:351–9. [PubMed: 1489671]
- (135). Griffiths JR. *Br J Cancer* 1991;64:425–7. [PubMed: 1911181]
- (136). Gillies RJ, Liu Z, Bhujwalla ZM. *Am J Physiol* 1994;267:C195–C203. [PubMed: 8048479]
- (137). van Sluis R, Bhujwalla ZM, Raghunand N, Ballesteros P, Alvarez J, Cerdan S, Galons JP, Gillies RJ. *Magn Reson Med* 1999;41:743–50. [PubMed: 10332850]
- (138). Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. *Clin Exp Metastasis* 1996;14:176–86. [PubMed: 8605731]
- (139). Raghunand N, Mahoney B, van Sluis R, Baggett B, Gillies RJ. *Neoplasia* 2001;3:227–35. [PubMed: 11494116]
- (140). Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Doseescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. *Cancer Res* 2009;69:2260–8. [PubMed: 19276390]
- (141). Gil S, Zaderenzo P, Cruz F, Cerdan S, Ballesteros P. *Bioorg Med Chem* 1994;2:305–14. [PubMed: 7922141]
- (142). Bhujwalla ZM, Artemov D, Ballesteros P, Cerdan S, Gillies RJ, Solaiyappan M. *NMR Biomed* 2002;15:114–9. [PubMed: 11870907]
- (143). Ojugo AS, McSheehy PM, McIntyre DJ, McCoy C, Stubbs M, Leach MO, Judson IR, Griffiths JR. *NMR Biomed* 1999;12:495–504. [PubMed: 10668042]
- (144). Mason RP. *Curr Med Chem* 1999;6:481–99. [PubMed: 10213795]
- (145). Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. *Magn Reson Med* 2006;55:309–315. [PubMed: 16402385]
- (146). Provent P, Benito M, Hiba B, Farion R, Lopez-Larrubia P, Ballesteros P, Remy C, Segebarth C, Cerdan S, Coles JA, Garcia-Martin ML. *Cancer Res* 2007;67:7638–45. [PubMed: 17699768]
- (147). Gil MS, Cruz F, Cerdan S, Ballesteros P. *Bioorganic & Medicinal Chemistry Letters* 1992;2:1717–1722.
- (148). Garcia-Martin ML, Herigault G, Remy C, Farion R, Ballesteros P, Coles JA, Cerdan S, Ziegler A. *Cancer Res* 2001;61:6524–31. [PubMed: 11522650]
- (149). Ward KM, Balaban RS. *Magn Reson Med* 2000;44:799–802. [PubMed: 11064415]
- (150). Aime S, Barge A, Delli Castelli D, Fedeli F, Mortillaro A, Nielsen FU, Terreno E. *Magn Reson Med* 2002;47:639–48. [PubMed: 11948724]
- (151). Woods M, Woessner DE, Sherry AD. *Chem Soc Rev* 2006;35:500–11. [PubMed: 16729144]
- (152). Cai S, Seu C, Kovacs Z, Sherry AD, Chen Y. *J Am Chem Soc* 2006;128:13474–8. [PubMed: 17031960]
- (153). Yoo B, Pagel MD. *Front Biosci* 2008;13:1733–52. [PubMed: 17981664]
- (154). Gianolio E, Napolitano R, Fedeli F, Arena F, Aime S. *Chem Commun (Camb)* 2009:6044–6. [PubMed: 19809638]

- (155). Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjaer-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM. *Nature* 2008;453:940–3. [PubMed: 18509335]
- (156). Gill SS, Thomas DG, Van Bruggen N, Gadian DG, Peden CJ, Bell JD, Cox IJ, Menon DK, Iles RA, Bryant DJ, et al. *J Comput Assist Tomogr* 1990;14:497–504. [PubMed: 2164536]
- (157). Weiner MW, Hetherington H, Hubesch B, Karczmar G, Massie B, Maudsley A, Meyerhoff DJ, Sappey-Marini D, Schaefer S, Twieg DB, et al. *NMR Biomed* 1989;2:290–7. [PubMed: 2701809]
- (158). Kurhanewicz J, Vigneron DB, Nelson SJ. *Neoplasia* 2000;2:166–89. [PubMed: 10933075]
- (159). Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, Wood PJ, Noworolski S, Nelson SJ, Barken I, Carroll PR, Kurhanewicz J. *Magn Reson Med* 2001;46:49–57. [PubMed: 11443710]
- (160). Jacobs MA, Barker PB, Argani P, Ouwerkerk R, Bhujwala ZM, Bluemke DB. *J Magn Reson Imaging* 2005;21:23–28. [PubMed: 15611934]
- (161). Lehnhardt FG, Bock C, Rohn G, Ernestus RI, Hoehn M. *NMR Biomed* 2005;18:371–82. [PubMed: 15959923]
- (162). Mountford CE, Somorjai RL, Malycha P, Gluch L, Lean C, Russell P, Barraclough B, Gillett D, Himmelreich U, Dolenko B, Nikulin AE, Smith IC. *Br J Surg* 2001;88:1234–40. [PubMed: 11531873]
- (163). Li X, Lu Y, Pirzkall A, McKnight T, Nelson SJ. *J Magn Reson Imaging* 2002;16:229–37. [PubMed: 12205577]
- (164). Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW. *Br J Cancer* 2006;94:427–35. [PubMed: 16465174]
- (165). Hu J, Vartanian SA, Xuan Y, Latif Z, Soulen RL. *Magn Reson Imaging* 2005;23:571–6. [PubMed: 15919603]
- (166). Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, Lu Y, Nelson S, McKnight TR. *Int J Radiat Oncol Biol Phys* 2005;62:20–31. [PubMed: 15850898]
- (167). Taylor JS, Langston JW, Reddick WE, Kingsley PB, Ogg RJ, Pui MH, Kun LE, Jenkins JJ 3rd, Chen G, Ochs JJ, Sanford RA, Heideman RL. *Int J Radiat Oncol Biol Phys* 1996;36:1251–61. [PubMed: 8985051]
- (168). Wald LL, Nelson SJ, Day MR, Noworolski SE, Henry RG, Huhn SL, Chang S, Prados MD, Sneed PK, Larson DA, Wara WM, McDermott M, Dillon WP, Gutin PH, Vigneron DB. *J Neurosurg* 1997;87:525–34. [PubMed: 9322843]
- (169). Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. *J Magn Reson Imaging* 2002;16:451–63. [PubMed: 12353259]
- (170). Carroll PR, Coakley FV, Kurhanewicz J. *Rev Urol* 2006;8(Suppl 1):S4–S10. [PubMed: 17021625]
- (171). Hricak H, Williams RD, Spring DB, Moon KL Jr. Hedgcock MW, Watson RA, Crooks LE. *AJR Am J Roentgenol* 1983;141:1101–10. [PubMed: 6196961]
- (172). Jacobs MA, Ouwerkerk R, Petrowski K, Macura KJ. *Top Magn Reson Imaging* 2008;19:261–72. [PubMed: 19512848]
- (173). Loening NM, Chamberlin AM, Zepeda AG, Gonzalez RG, Cheng LL. *NMR Biomed* 2005;18:413–20. [PubMed: 16075415]
- (174). Nelson SJ, Graves E, Pirzkall A, Li X, Antiniw Chan A, Vigneron DB, McKnight TR. *J Magn Reson Imaging* 2002;16:464–76. [PubMed: 12353260]
- (175). Zaider M, Zelefsky MJ, Lee EK, Zakian KL, Amols HI, Dyke J, Cohen G, Hu Y, Endi AK, Chui C, Koutcher JA. *Int J Radiat Oncol Biol Phys* 2000;47:1085–96. [PubMed: 10863082]
- (176). Sawyers CL. *Nature* 2008;452:548–52. [PubMed: 18385728]
- (177). Weissleder R, Pittet MJ. *Nature* 2008;452:580–9. [PubMed: 18385732]
- (178). Medarova Z, Pham W, Farrar C, Petkova V, Moore A. *Nat Med* 2007;13:372–7. [PubMed: 17322898]
- (179). Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. *Radiology* 2002;222:715–21. [PubMed: 11867790]
- (180). Haddadin IS, McIntosh A, Meisamy S, Corum C, Styczynski Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. *NMR Biomed* 2009;22:65–76. [PubMed: 17957820]

- (181). Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, Carroll PR. *Radiology* 1996;200:489–96. [PubMed: 8685346]
- (182). Gillies RJ, Bhujwalla ZM, Evelhoch J, Garwood M, Neeman M, Robinson SP, Sotak CH, Van Der Sanden B. *Neoplasia* 2000;2:139–51. [PubMed: 10933073]
- (183). Evelhoch JL, Gillies RJ, Karczmar GS, Koutcher JA, Maxwell RJ, Nalcioğlu O, Raghunand N, Ronen SM, Ross BD, Swartz HM. *Neoplasia* 2000;2:152–65. [PubMed: 10933074]
- (184). Schwarz AJ, Maisey NR, Collins DJ, Cunningham D, Huddart R, Leach MO. *Br J Radiol* 2002;75:959–66. [PubMed: 12515704]
- (185). deSouza NM, Soutter WP, Rustin G, Mahon MM, Jones B, Dina R, McIndoe GA. *Br J Cancer* 2004;90:2326–31. [PubMed: 15162152]
- (186). Belouèche-Babari M, Jackson LE, Al-Saffar NM, Workman P, Leach MO, Ronen SM. *Cancer Res* 2005;65:3356–63. [PubMed: 15833869]
- (187). Ross J, Najjar AM, Sankaranarayananpillai M, Tong WP, Kaluarachchi K, Ronen SM. *Mol Cancer Ther* 2008;7:2556–65. [PubMed: 18723500]
- (188). Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, Eckhardt SG, Serkova NJ. *Br J Cancer* 2009;100:923–31. [PubMed: 19259085]
- (189). Sankaranarayananpillai M, Tong WP, Yuan Q, Bankson JA, Dafni H, Bornmann WG, Soghomonyan S, Pal A, Ramirez MS, Webb D, Kaluarachchi K, Gelovani JG, Ronen SM. *Mol Imaging* 2008;7:92–100. [PubMed: 18706291]
- (190). Al-Saffar NM, Troy H, Ramirez de Molina A, Jackson LE, Madhu B, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung YL. *Cancer Res* 2006;66:427–34. [PubMed: 16397258]
- (191). Krishnamachary B, Glunde K, Wildes F, Mori N, Takagi T, Raman V, Bhujwalla ZM. *Cancer Res* 2009;69:3464–71. [PubMed: 19336572]
- (192). Campos JM, Nunez MC, Sanchez RM, Gomez-Vidal JA, Rodriguez-Gonzalez A, Banez M, Gallo MA, Lacal JC, Espinosa A. *Bioorg Med Chem* 2002;10:2215–31. [PubMed: 11983519]
- (193). Lacal JC. *IDrugs* 2001;4:419–26. [PubMed: 16015482]
- (194). Meister G, Tuschl T. *Nature* 2004;431:343–9. [PubMed: 15372041]
- (195). Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. *Nature* 1998;391:806–11. [PubMed: 9486653]
- (196). Gallagher FA, Kettunen MI, Hu DE, Jensen PR, Zandt RI, Karlsson M, Gisselsson A, Nelson SK, Whitney TH, Bohndiek SE, Hansson G, Peitersen T, Lerche MH, Brindle KM. *Proc Natl Acad Sci U S A* 2009;106:19801–6. [PubMed: 19903889]
- (197). Artemov D, Solaiyappan M, Bhujwalla ZM. *Cancer Res* 2001;61:3039–44. [PubMed: 11306485]
- (198). Kato Y, Holm DA, Okollie B, Artemov D. *Neuro Oncol* 2010;12:71–9. [PubMed: 20150369]
- (199). Wolf W, Presant CA, Waluch V. *Adv Drug Deliv Rev* 2000;41:55–74. [PubMed: 10699305]
- (200). van Laarhoven HW, Klomp DW, Rijpkema M, Kamm YL, Wagener DJ, Barentsz JO, Punt CJ, Heerschap A. *NMR Biomed* 2007;20:128–40. [PubMed: 17006886]
- (201). Li C, Penet MF, Winnard P Jr, Artemov D, Bhujwalla ZM. *Clin Cancer Res* 2008;14:515–22. [PubMed: 18223227]
- (202). Reid DG, Murphy PS. *Drug Discov Today* 2008;13:473–80. [PubMed: 18549972]
- (203). Yu, J-X.; Cui, W.; Zhao, D.; Mason, RP. *Fluorine and Health*. Tressaud, A.; Haufe, G., editors. Elsevier B.V.; Amsterdam: 2008.
- (204). Kato Y, Okollie B, Artemov D. *Magn Reson Med* 2006;55:755–61. [PubMed: 16508914]
- (205). Griffiths JR, Glickson JD. *Adv Drug Deliv Rev* 2000;41:75–89. [PubMed: 10699306]
- (206). O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, et al. *Eur J Cancer* 1993;29A:940–2. [PubMed: 8499146]
- (207). Gillies RJ, Raghunand N, Garcia-Martin ML, Gatenby RA. *IEEE Eng Med Biol Mag* 2004;23:57–64. [PubMed: 15565800]

Figure 1.

Schematic of the components of a tumor. Cancer cells are embedded within the extracellular matrix (ECM). The ECM consists of a complex meshwork of structural extracellular proteins. The tumor microenvironment (TME) contains the ECM and stromal cells such as endothelial cells, fibroblasts, and macrophages that are co-opted by the tumor. The TME is typically characterized by hypoxia, acidic extracellular pH, and substrate depletion.

^1H MRS **^{31}P MRS** **^{13}C MRS - $[1\text{-}^{13}\text{C}]$ -glucose** **^{19}F MRS - $[5\text{-}^{19}\text{F}]$ -fluorocytosine** **Figure 2.**

Examples of multi-nuclear MRS applications. From top to bottom: Representative *in vivo* single-voxel ^1H MRS of an MDA-MB-231 breast tumor xenograft model obtained at 4.7T, and *ex vivo* high-resolution ^1H MRS of a water-soluble MDA-MB-231 cell extract obtained at 11.7T.¹⁷ The insert shows an expanded region around 3.2 ppm demonstrating that human breast cancer cells exhibit low GPC levels, high PC levels and high levels of total choline-containing metabolites. Representative *in vivo* single-voxel ^{31}P MRS of an MDA-MB-231 breast tumor model obtained at 4.7T.¹⁹¹ Time course of *in vivo* ^{13}C MRS of a RIF-1 tumor obtained at 9.4T using heteronuclear cross polarization.⁵² The animal was injected with 900 mg/kg of $[1\text{-}^{13}\text{C}]$ -labeled D-glucose. The glycolytic rate of the tumor can be determined by

kinetic analysis of [3-¹³C]-lactate build-up. Representative *in vivo* ¹⁹F MRS of the conversion of prodrug to anticancer drug in an MDA-MB-231 breast tumor model.²⁰¹ The animal was injected with 450 mg/kg of [5-¹⁹F]-fluorocytosine at 24 h after injection of a cytosine deaminase-containing nanoplex, and the conversion of the pro-drug [5-¹⁹F]-fluorocytosine to the anticancer drug [5-¹⁹F]-fluorouracil was followed by ¹⁹F MRS at 4.7T. Assignments: Cho, free choline; 5-FC, [5-¹⁹F]-fluorocytosine; 5-FU, [5-¹⁹F]-fluorouracil; GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine; NAD, nicotinamide adenine dinucleotide; DPDE, diphosphodiester; NDP, nucleoside diphosphate; NTP, nucleoside triphosphate; Lac, lactate; Lip-CH₂-, methylene groups of mobile lipids; Lip-CH₃, methyl groups of mobile lipids; PC, phosphocholine; PE, phosphoethanolamine; PCr, phosphocreatine; Pi, inorganic phosphate; tCho, total choline-containing compounds (Cho+PC+GPC). Adapted from +++^{17,52,191,201}.

Figure 3.

CEST imaging of lysine rich-protein (LRP) reporter. (A) Frequency-selective radiofrequency pulses excite the amide protons. These protons exchange with water protons, thereby reducing the MRSI signal intensity (SI) of the water signal by ΔSI . (B) *Ex vivo* proof-of-principle MRSI of the LRP reporter protein in phantoms demonstrated that the LRP-containing phantom displayed significantly higher ΔSI when excited at ± 3.76 ppm as compared to poly-L-lysine, phosphate-buffered saline, or green fluorescent protein as controls (scale bar, 1 mm). (C) Anatomical image (left) and CEST signal intensity-difference map overlaid on the anatomical image (right) was able to distinguish the LRP-expressing and control tumor xenografts. Adapted from¹¹⁴.

Figure 4.

Combined MRI, DWI/ADC mapping, and MRSI of the prostate at 1.5T. (A) Axial T₂-weighted image and three-dimensional MRSI spectral grid. The arrows indicate a region of prostate cancer. (B) Corresponding MRSI spectral array, showing the presence of an aggressive tumor (elevated total choline and reduced citrate) on the left side of the gland (right side of the image). (C) Image of the apparent diffusion coefficient of water demonstrates a region of prostate cancer (arrows) in the same location as the T₂-weighted image and MRSI. (D) Representative spectra taken from the region of healthy prostate tissue (left) and prostate cancer (right). Adapted from¹⁷⁰.

Figure 5.

Demonstration of T₂-weighted image, DWI/ADC map, MRS, and DCE-MRI of a 55 year old man with suspected prostate cancer (Gleason score =7). Multi-parametric MRI of the prostate gland revealed focal areas of “dark” T₂ signal bilaterally with corresponding decreased ADC in the left/mid area of the gland ($0.41 \pm 0.13 \times 10^{-3} \text{ mm}^2/\text{s}$) and $0.97 \pm 0.34 \times 10^{-3} \text{ mm}^2/\text{s}$ on the right side (although a smaller region). DCE-MRI kinetics detect increased permeability and extra-vascular fraction in the right and left mid gland areas that are correlated to the Gleason score 7. Moreover, both sides show evidence of increased total choline and decreased citrate by MRS.

Figure 6.

(A) Sagittal three-dimensional gadolinium-enhanced fat-suppressed MR images (left) and corresponding spectra (right) of the right breast in a 42-year-old **nonresponder** with invasive ductal carcinoma. (B) Sagittal three-dimensional gadolinium-enhanced fat-suppressed MR images (left) and corresponding spectra (right) of the right breast in a 43-year-old objective **responder** with invasive ductal carcinoma and positive lymph nodes. On MR images, boxes surrounding enhancing lesions depict spectroscopy voxels. The labeled spectral peaks arise from lipid (1), tCho (2), and water (3). Assignments: tCho, total choline-containing compounds; LD, longest diameter. Adapted from⁵.

Figure 7.

(A) *In vivo* single-voxel ³¹P MRS of MDA-MB-231 tumor xenografts. (A) Representative *in vivo* single-voxel ³¹P MRS of MDA-MB-231 tumor xenografts following systemic delivery of lentivirus expressing control shRNA that targets luciferase (luc-shRNA, left) or Chk-targeting shRNA (chk-shRNA, right). Chk-shRNA injection resulted in a significant reduction of PC (arrow) as compared to luc-shRNA. (B) Tumor growth rates were significantly reduced with lentivirus-mediated Chk targeting as compared to control luc-shRNA transduced controls. Tumor volume of luc-shRNA (gray circles, n=5) and chk-shRNA (black circles, n=5) transduced tumors is given in mm³. Values represent mean and standard error. * P < 0.075. (C) Representative brightfield and fluorescence photomicrographs of tumor sections showing distribution of enhanced green fluorescent protein (EGFP), which was expressed from the lentiviral vectors as delivery control, in luc-shRNA (upper panel) and chk-shRNA (lower panel) transduced tumors. This demonstrated successful delivery of lentiviruses into tumors following tail vein injection. Assignments: chk-shRNA, treated with lentivirus targeting choline kinase (chk) with specific short-hairpin RNA; DPDE, diphosphodiester; luc-shRNA; treated with lentivirus targeting luciferase (luc) with specific short-hairpin RNA as vector control; NAD, Nucleoside adenosine diphosphate; NTP, Nucleoside triphosphate; PC, phosphocholine; PDE, phosphodiester; PCr, phosphocreatine; PE, phosphoethanolamine; PME, phosphomonoester. Adapted from¹⁹¹.

Table 1

Nuclei commonly studied in order of sensitivity of detection and some of their preclinical (+) and clinical (*) applications in cancer. The intensity of the MR signal depends on the concentration of nuclear spins, and the gyromagnetic ratio γ of the spins. The detection limits of ^1H and ^{19}F MRS are typically within the mM range, with higher concentrations required for less-sensitive nuclei such as ^{31}P and ^{13}C .

Nucleus	γ [MHz/T]	Sensitivity of detection	Applications
^1H	42.58		<ul style="list-style-type: none"> • Total choline+* • Lactate+* • Lipid+* • N-acetyl-aspartate+ • Citrate+ • Extracellular pH (pHe)+ • Treatment efficacy+* • Detection of metastasis+* • pO2+
^{19}F	40.08		<ul style="list-style-type: none"> • Drug pharmacokinetics+* • pHe+ • pO2+ • Enzyme activity+ • Labeled substrate utilization+
^{31}P	17.25		<ul style="list-style-type: none"> • Energy metabolism (ATP, PCr, Pi)+* • Intracellular pH (pHi)+* • Phospholipid metabolism+*
^{13}C	10.71		<ul style="list-style-type: none"> • Labeled substrate utilization to evaluate drug pharmacokinetics and metabolic pathways+*

Table 2

Chemical structures of metabolites referred to in this review article.

Compound Name	Chemical Structure
N-acetyl aspartate	<p>The chemical structure of N-acetyl aspartate is shown. It consists of an aspartate moiety (a four-carbon chain with a carboxylic acid group at one end and an amide group at the other) where the nitrogen atom of the amide group is acetylated (bonded to a methyl group). The structure is drawn in a skeletal format with explicit hydrogen and oxygen atoms.</p> <chem>CC(=O)N[C@@H](CC(=O)O)CC(=O)O</chem>
Citrate	<p>The chemical structure of Citrate is shown. It is a tricarboxylic acid, specifically 2-hydroxy-1,2,3-propanetricarboxylic acid. The central carbon atom is bonded to a hydroxyl group and three carboxymethyl groups. The structure is drawn in a skeletal format with explicit hydrogen and oxygen atoms.</p> <chem>OC(CC(=O)O)(CC(=O)O)CC(=O)O</chem>

Compound Name	Chemical Structure
Glucose, [1- ¹³ C]-/[U- ¹³ C]-glucose	<p>and/or</p>
Lactate, [3- ¹³ C]-lactate

Compound Name	Chemical Structure
Pyruvate	<p>The chemical structure of pyruvate is shown. It consists of a central carbon atom (C2) double-bonded to an oxygen atom (O) above it and single-bonded to a methyl group (CH3) to its left. This central carbon is also single-bonded to another carbon atom (C1) to its right, which is double-bonded to an oxygen atom (O) above it and single-bonded to a hydroxyl group (OH) to its right.</p>
[1,4- ¹³ C ₂]-fumarate	<p>The chemical structure of [1,4-¹³C₂]-fumarate is shown. It is a trans-butenedioate ion, consisting of a central carbon-carbon double bond. Each carbon is single-bonded to a carboxyl group (COOH). The structure is drawn in a trans configuration, with the two carboxyl groups on opposite sides of the double bond.</p>

Compound Name	Chemical Structure
Choline (Cho)
Phosphocholine (PC)
Glycerophosphocholine (GPC)
Phosphoethanolamine (PE)

Compound Name	Chemical Structure
<p>Glycerophosphoethanolamine (GPE)</p>
<p>Triacylglycerides, example of C₅₅H₉₈O₆, palmitic acid, oleic acid, alpha-linolenic acid (from top to bottom)</p>

Compound Name	Chemical Structure
Nucleoside triphosphates (NTP), example of ATP	
Nucleoside diphosphates (NDP), example of ADP	
Phosphocreatine (PCr)	
Inorganic phosphate (Pi)	

Table 3

blecules referred to in this review article.

Chemical Structure	Detected Nuclei	Reported Property	Required Concentration	References
¹ H	Oxygen Tension	Direct tissue injection of 50 µl pure HMDSO 11	11,126
¹⁹ F	Oxygen Tension	Direct tissue injection of 40 µl pure HFB 125	125,126
¹⁹ F	Oxygen Tension	75 mg/kg intravenous injection of TF-MISO (dissolved in saline) 129	128 – 130
	³¹ P, pH-dependent, chemical shift	pH, mostly pHi	Endogenous, ~1 mM	57,58,96–101

Chemical Structure	Detected Nuclei	Reported Property	Required Concentration	References
^{31}P	pHe	Intraperitoneal injection of 0.3 ml of 63.8 mg/ml 3-APP in saline 136	136,207
^1H	pHe	Intraperitoneal injection of 0.15 ml of 310 mM IEPA solution per 25 mg mouse 137,142,148	137,142,148
^1H CEST	Endogenous tissue pH, biodegradable molecular imaging reporter	~50 mM	112,113,149
^1H ParaCEST	No in vivo studies available	~10 mM	150 – 153

Chemical Structure	Detected Nuclei	Reported Property	Required Concentration	References
Hyper-polarized ^{13}C	Tissue pH	Catheter-based intravenous injection of 0.2 ml of 100 mM hyperpolarized $\text{H}^{13}\text{CO}_3^-$ solution 155	155
^{19}F	Drug Delivery and Metabolism of Chemotherapeutic Agent 5-FU	Humans are given a ~0.7 mM dose of $[5-^{19}\text{F}]\text{-FU}$ 199	199

Chemical Structure	Detected Nuclei	Reported Property	Required Concentration	References
<chem>Nc1cc(NC(=O)N2C=CC(=O)N2)c(F)c1</chem>	^{19}F	Pro-drug Therapy	Intraperitoneal injection of 5-FC at a dose of 450 mg/kg ²⁰¹	201

Chem Rev. Author manuscript; available in PMC 2011 May 12.

Chemical Structure	Detected Nuclei	Reported Property	Required Concentration	References
<chem>CN1C=NC2=C1C(=O)N(C)C2=O</chem>	¹³ C	Drug Delivery of TMZ	Catheter-based intraperitoneal infusion of 0.3 ml of 3 mg/ml [¹³ C] TMZ in saline ²⁰⁴	204

Chem. Rev. Author manuscript; available in PMC 2011 May 12.